Amgen Inc. raised its full-year 2026 revenue forecast to between $38.9 billion and $39.7 billion following strong third-quarter sales of $10.4 billion. Quarterly revenue grew 8% year-over-year, driven by demand for cholesterol drug Repatha and lung cancer treatment Imdelltra. Adjusted earnings reached $6.45 per share, beating Wall Street expectations. Meanwhile, Amgen is pushing back against a proposed FDA withdrawal of its autoimmune drug Tavneos and advancing Phase 3 trials for its MariTide weight-loss therapy.
Q3 2026 financial results
- ▪Amgen Inc. reported third-quarter 2026 adjusted earnings per share of $6.45, exceeding average analyst estimates of $5.77 to $5.79 per share
- ▪Amgen Inc. reported third-quarter 2026 overall revenue of $10.4 billion, representing an 8% increase from the prior year and beating Wall Street estimates of $10.1 billion
Repatha sales and competition
- ▪Repatha, an injectable PCSK9 cholesterol therapy administered monthly or biweekly, faces competition from Merck & Co.'s daily oral pill Lipfendra
- ▪Third-quarter 2026 sales of Amgen Inc.'s cholesterol drug Repatha increased 37% year-over-year to $1.09 billion, exceeding analysts' expectations of $1.04 billion
Imdelltra performance and clinical developments
- ▪Third-quarter 2026 sales of Amgen Inc.'s small cell lung cancer drug Imdelltra rose 128% year-over-year to $406 million, driven by volume growth
- ▪A study reported last month indicated that combining Imdelltra with AstraZeneca Plc's Imfinzi improved survival in patients with non-progressed lung cancer following chemotherapy
Full-year 2026 financial outlook
- ▪Amgen Inc. raised its full-year 2026 adjusted earnings forecast to a range of $22.90 to $23.70 per share
- ▪Amgen Inc. raised its full-year 2026 revenue forecast to a range of $38.9 billion to $39.7 billion, up from a previous guidance range of $38.2 billion to $39.4 billion
MariTide obesity drug development
- ▪Initial results from Amgen Inc.'s Phase 3 trials for experimental weight-loss drug MariTide are expected in 2027
- ▪Amgen Inc. is developing MariTide as an injection administered as infrequently as four times annually to treat obesity, sleep apnea, and heart disease
Tavneos sales and regulatory challenges
- ▪Third-quarter 2026 sales of Amgen Inc.'s rare autoimmune disease drug Tavneos fell 2% year-over-year to $105 million
- ▪Amgen Inc. continues to engage with the U.S. Food and Drug Administration regarding Tavneos, asserting that the drug possesses a favorable benefit-risk profile
- ▪In April 2026, the U.S. Food and Drug Administration proposed withdrawing Tavneos from the market due to lack of proven effectiveness and trial data integrity concerns
Story comments
Loading comments…